Cisplatin and other platinum-based medications commonly used in cancer treatment are non-selective and harm both cancerous and healthy cells, prompting research into more targeted therapies. One approach involves using metal ions like Ru(II) and Rh(III) instead of platinum, aiming to selectively destroy cancer cells and minimize side effects. My thesis research involved studying the interactions of rhodium ions with pyridinone derivatives, utilizing techniques like pH-potentiometry, 1H-NMR spectroscopy, and ESI-MS. The results consistently showed the formation of stable complexes, with variations in complex types depending on pH and metal-to-ligand ratios. However, due to time constraints, the potential hydrolysis of the metal ion could not be conclusively investigated.